share_log

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023

Elite Pharmicals, Inc. 将于2023年11月15日主持电话会议,提供公司最新情况并讨论2024年第二季度财务业绩
Accesswire ·  2023/11/10 11:30

Financials for Second Quarter Fiscal Year 2024 Ended September 30, 2023 will be released on November 14, 2023

截至2023年9月30日的2024财年第二季度财务状况将于2023年11月14日公布

NORTHVALE, NJ / ACCESSWIRE / November 10, 2023 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2024 fiscal year will be released on Tuesday, November 14, 2023. Elite's management will host a live conference call on Wednesday, November 15th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update. Stockholders should submit questions to the company before the call.

新泽西州诺斯维尔/ACCESSWIRE/2023年11月10日/开发利基仿制药产品的专业制药公司Elite Pharmicals, Inc.(“精英” 或 “公司”)(场外交易股票代码:ELTP)今天宣布,2024财年第二季度财务业绩将于2023年11月14日星期二公布。Elite的管理层将于11月15日星期三主持电话会议直播第四,美国东部标准时间上午 11:30,将讨论公司的财务和经营业绩,并提供一般业务最新情况。股东应在电话会议之前向公司提交问题。

Date: November 15, 2023
Time: 11:30 AM EST
Dial-in numbers: 1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number: 98840
Questions: dianne@elitepharma.com
General questions by 5:00 PM EDT on Sunday, November 12, 2023
Financial questions by 7:00 PM EDT on Tuesday, November 14, 2023
Audio Replay:
日期: 2023年11月15日
时间: 美国东部时间上午 11:30
拨入号码: 1-800-346-7359(国内)
1-973-528-0008(国际)
会议号码: 98840
问题: dianne@elitepharma.com
在 2023 年 11 月 12 日星期日美国东部时间下午 5:00 之前提出一般性问题
2023 年 11 月 14 日星期二美国东部时间晚上 7:00 之前提出财务问题
音频重播:

About Elite Pharmaceuticals, Inc.

关于精英制药有限公司

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit .

Elite Pharmicals, Inc. 是一家开发和分销利基仿制药的专业制药公司。Elite 专门开发和制造口服控释药物产品。Elite拥有多种仿制药,其中一些已获得Prasco, LLC和TAGI Pharma的许可。Elite在新泽西州诺斯维尔经营着一个注册的cGMP和DEA的研究、开发和制造设施。欲了解更多信息,请访问。

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

本新闻稿包含1995年《私人证券诉讼改革法》所指的 “前瞻性陈述”,包括但不限于与可能与本新闻稿主题相关的对未来业绩、业绩或其他预期的影响(如果有)相关的陈述。提醒读者,此类前瞻性陈述涉及但不限于Elite无法控制的风险、不确定性和其他因素,这些因素可能导致Elite的实际业绩、表现或成就与这些前瞻性陈述可能暗示的结果、业绩或其他预期存在重大差异。这些前瞻性陈述可能包括有关FDA批准产品的预期时间(如果有的话)的陈述,以及FDA可能要求Elite采取行动以获得此类批准的陈述。这些前瞻性陈述不能保证未来的行动或表现。Elite向美国证券交易委员会提交的文件,包括其关于10-K、10-Q和8-K表的报告,无限制地讨论了这些风险和其他因素。无论是由于新信息、未来事件还是其他原因,Elite都没有义务更新或更改其前瞻性陈述。

Contact:

联系人:

For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com

适用于精英制药公司
戴安娜·威尔,投资者关系,518-398-6222
Dianne@elitepharma.com

SOURCE: Elite Pharmaceuticals, Inc.

来源:精英制药公司


View source version on accesswire.com:
在 accesswire.com 上查看源代码版本:

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发